The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients

被引:122
作者
Lobaton, Triana [1 ]
Bessissow, Talat [2 ]
De Hertogh, Gert [3 ]
Lemmens, Bart [3 ]
Maedler, Chelsea [4 ]
Van Assche, Gert [1 ]
Vermeire, Severine [1 ]
Bisschops, Raf [1 ]
Rutgeerts, Paul [1 ]
Bitton, Alain [2 ]
Afif, Waqqas [2 ]
Marcus, Victoria [4 ]
Ferrante, Marc [1 ]
机构
[1] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Gastroenterol, B-3000 Louvain, Belgium
[2] Royal Victoria Hosp, Dept Gastroenterol, Montreal, PQ H3A 1A1, Canada
[3] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Pathol, B-3000 Louvain, Belgium
[4] Royal Victoria Hosp, Dept Pathol, Montreal, PQ H3A 1A1, Canada
关键词
Endoscopic scores; ulcerative colitis; disease extent; TERM-FOLLOW-UP; DOUBLE-BLIND; FECAL CALPROTECTIN; COMBINATION THERAPY; DISEASE-ACTIVITY; NATURAL-HISTORY; OPEN-LABEL; VALIDATION; INFLIXIMAB; PROCTOSIGMOIDITIS;
D O I
10.1093/ecco-jcc/jjv111
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aims: Current endoscopic activity scores for ulcerative colitis (UC) do not take into account the extent of mucosal inflammation. We have developed a simple endoscopic index for UC that takes into account the severity and distribution of mucosal inflammation. Methods: In this multicentre trial, UC patients undergoing colonoscopy were prospectively enrolled. For the Modified Score (MS), the sum of Mayo Endoscopic Subscores (MESs) for five colon segments (ascending, transverse, descending, sigmoid and rectum) was calculated. The Extended Modified Score (EMS) was obtained by multiplying the MS by the maximal extent of inflammation. The Modified Mayo Endoscopic Score (MMES) was obtained by dividing the EMS by the number of segments with active inflammation. Colon biopsies were obtained from the rectum and sigmoid, as well as from all inflamed segments, by standard methods. Clinical activity was scored according to the Partial Mayo Score (PMS). Biological activity was scored according to C-reactive protein (CRP) and faecal calprotectin (FC) levels. Histological activity was scored according to the Geboes Score (GS). Results: One hundred and seventy-one UC patients (38% female, median age 47 years, median disease duration 13 years) were included. The MMES correlated significantly with the PMS (r = 0.535), CRP (r = 0.238), FC (r = 0.730) and GS (r = 0.615) (all p < 0.001). Median MMES scores were significantly higher in patients with clinical, biological or histological activity (all p = 0.001) Conclusions: The MMES is an easy to use endoscopic index for UC that combines the severity analysis of the MES with disease extent, and correlates very well with clinical, biological and histological disease activity.
引用
收藏
页码:846 / 852
页数:7
相关论文
共 43 条
[1]   Open-Label Study of Adalimumab in Patients with Ulcerative Colitis Including Those with Prior Loss of Response or Intolerance to Infliximab [J].
Afif, Waqqas ;
Leighton, Jonathan A. ;
Hanauer, Stephen B. ;
Loftus, Edward V., Jr. ;
Faubion, William A. ;
Pardi, Darrell S. ;
Tremaine, William J. ;
Kane, Sunanda V. ;
Bruining, David H. ;
Cohen, Russell D. ;
Rubin, David T. ;
Hanson, Karen A. ;
Sandborn, William J. .
INFLAMMATORY BOWEL DISEASES, 2009, 15 (09) :1302-1307
[2]   Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis [J].
Ardizzone, Sandro ;
Cassinotti, Andrea ;
Duca, Piergiorgio ;
Mazzali, Cristina ;
Penati, Chiara ;
Manes, Gianpiero ;
Marmo, Riccardo ;
Massari, Alessandro ;
Molteni, Paola ;
Maconi, Giovanni ;
Porro, Gabriele Bianchi .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2011, 9 (06) :483-U117
[3]   Progression of ulcerative proctosigmoiditis: Incidence and factors influencing progression [J].
Ayres, RC ;
Gillen, CD ;
Walmsley, RS ;
Allan, RN .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1996, 8 (06) :555-558
[4]   VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS [J].
BARON, JH ;
CONNELL, AM ;
LENNARDJONES, JE .
BRITISH MEDICAL JOURNAL, 1964, 1 (5374) :89-+
[5]   Prognostic Value of Serologic and Histologic Markers on Clinical Relapse in Ulcerative Colitis Patients With Mucosal Healing [J].
Bessissow, Talat ;
Lemmens, Bart ;
Ferrante, Marc ;
Bisschops, Raf ;
Van Steen, Kristel ;
Geboes, Karel ;
Van Assche, Gert ;
Vermeire, Severine ;
Rutgeerts, Paul ;
De Hertogh, Gert .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (11) :1684-1692
[6]   Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis [J].
Bitton, A ;
Peppercorn, MA ;
Antonioli, DA ;
Niles, JL ;
Shah, S ;
Bousvaros, A ;
Ransil, B ;
Wild, G ;
Cohen, A ;
Edwardes, MDD ;
Stevens, AC .
GASTROENTEROLOGY, 2001, 120 (01) :13-20
[7]   Feasibility of Endoscopic Assessment and Treating to Target to Achieve Mucosal Healing in Ulcerative Colitis [J].
Bouguen, Guillaume ;
Levesque, Barrett G. ;
Pola, Suresh ;
Evans, Elisabeth ;
Sandborn, William J. .
INFLAMMATORY BOWEL DISEASES, 2014, 20 (02) :231-239
[8]   Factors associated with disease evolution in Greek patients with inflammatory bowel disease [J].
Chatzicostas, Constantinos ;
Roussomoustakaki, Maria ;
Potamianos, Spiros ;
Paspatis, Gregorios ;
Mouzas, Ioannis ;
Romanos, John ;
Mavrogeni, Helen ;
Kouroumalis, Elias .
BMC GASTROENTEROLOGY, 2006, 6 (1)
[9]   Long-term Follow-up of Ulcerative Colitis in the Chinese Population [J].
Chow, Dorothy K. L. ;
Leong, Rupert W. L. ;
Tsoi, Kelvin K. F. ;
Ng, Simon S. M. ;
Leung, Wai-keung ;
Wu, Justin C. Y. ;
Wong, Vincent W. S. ;
Chan, Francis K. L. ;
Sung, Joseph J. Y. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (03) :647-654
[10]   Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis [J].
Colombel, Jean Frederic ;
Rutgeerts, Paul ;
Reinisch, Walter ;
Esser, Dirk ;
Wang, Yanxin ;
Lang, Yinghua ;
Marano, Colleen W. ;
Strauss, Richard ;
Oddens, Bjoern J. ;
Feagan, Brian G. ;
Hanauer, Stephen B. ;
Lichtenstein, Gary R. ;
Present, Daniel ;
Sands, Bruce E. ;
Sandborn, William J. .
GASTROENTEROLOGY, 2011, 141 (04) :1194-1201